Acute Myeloid Leukemia Clinical Trial
Official title:
A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of CMV-MVA Triplex Vaccine in Adult Recipients of Haploidentical Hematopoietic Stem Cell Transplant
Verified date | December 2023 |
Source | City of Hope Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial studies how well Triplex vaccine works in preventing cytomegalovirus (CMV) infection in patients undergoing a hematopoietic stem cell transplantation. CMV is a virus that may be carried for life and does not cause illness in most healthy individuals. However, in people whose immune systems are lowered (such as those undergoing stem cell transplantation), CMV can reproduce and cause disease and even death. The Triplex vaccine is made up of 3 small pieces of CMV deoxyribonucleic acid (DNA) (the chemical form of genes) placed into a weakened virus called modified vaccinia Ankara (MVA) that may help produce immunity (the ability to recognize and respond to an infection) and reduce the risk of developing complications related to CMV infection.
Status | Active, not recruiting |
Enrollment | 12 |
Est. completion date | April 7, 2030 |
Est. primary completion date | April 7, 2030 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - All subjects must have the ability to understand and the willingness to sign a written informed consent - Participant must be willing to comply with study and/or follow-up procedures, including willingness to be followed for one year post-HCT - Planned peripheral blood stem cell (PBSC) or bone marrow (BM) HCT for the treatment of the following hematologic malignancies: - Lymphoma (Hodgkin and non-Hodgkin) - Myelodysplastic syndrome - Acute lymphoblastic leukemia in first or second remission (for acute lymphoblastic leukemia/lymphoblastic lymphoma, the disease status must be in hematologic remission by bone marrow and peripheral blood. Persistent lymphadenopathy on computed tomography [CT] or CT/positron emission tomography [PET] scan without progression is allowed.) - Acute myeloid leukemia in first or second remission - Chronic myelogenous leukemia in first chronic or accelerated phase, or in second chronic phase - Other hematologic malignancies judged appropriate by the clinical principal investigators (PIs), including chronic lymphocytic leukemia, myeloproliferative disorders and myelofibrosis. Patients with multiple myeloma and those with non-malignant disease such as aplastic anemia are excluded - Adult cases of multiple myeloma (MM) are excluded as HCT is not standard of care for MM, and is only performed in very advanced cases with an associated high risk of relapse and NRM. Adults with aplastic anemia are excluded because their standard management includes T cell depletion with agents such as anti-thymocyte globulin (ATG), which is not permissible on this protocol. Patients undergoing a second haploHCT are not eligible (patients who have undergone a previous autologous HCT are eligible) - Patients receiving myeloablative (MA) or reduced intensity conditioning (RIC) are allowed - CMV seropositive (recipient) - Planned related HCT with molecular 3/6 (haploidentical) intermediate/high resolution HLA donor allele matching - Planned HCT with minimal to no-T cell depletion of graft - Conditioning and immunosuppressive regimens according to institutional guidelines are permitted - Negative serum or urine beta human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration - Seronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and active hepatitis B virus (HBV) (surface antigen negative) within 2 months of registration and no history of disseminated cutaneous human papillomavirus (HPV) related disease - Agreement by females of childbearing potential and sexually active males to use an effective method of contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for up to d90 post-HCT. Should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately Exclusion Criteria: - Any prior investigational CMV vaccine - Experimental anti-CMV chemotherapy in the last 6 months - Live attenuated vaccines (from the time of HCT to d70 post-HCT) - Medically indicated subunit (Engerix-B for HBV; Gardasil for HPV) or killed vaccines (e.g. influenza, pneumococcal, or allergy treatment with antigen injections) (from the time of HCT to d70 post-HCT) - Allergy treatment with antigen injections (from the time of HCT to d70 post-HCT) - Alemtuzumab or any equivalent in vivo T-cell depleting agent (or CD34+ selection) (from the time of HCT to d70 post-HCT) - Antiviral medications with known therapeutic effects on CMV such as ganciclovir (GCV)/valganciclovir (VAL), foscarnet (FOS), cidofovir, CMX-001, maribavir. Acyclovir has no known therapeutic efficacy against CMV and is allowable as standard of care to prevent herpes simplex virus (HSV) (from the time of HCT to d70 post-HCT) - Prophylactic therapy with CMV immunoglobulin or prophylactic antiviral CMV treatment EXCEPT Prevymis prophylaxis (prior to d100) (from the time of HCT to d70 post-HCT) - Conditioning regimens d30 prior to trial participation and up to d180 post-HCT - Disease-based radiation therapy (not total body irradiation) (from the time of HCT to d70 post-HCT) - Other investigational product - concurrent enrollment in other clinical trials using any investigational new drugs (IND) with unknown effects on CMV or with unknown toxicity profiles is prohibited (from the time of HCT to d70 post-HCT) - Other medications that might interfere with the evaluation of the investigational product (from the time of HCT to d70 post-HCT) - Patients with active autoimmune conditions requiring systemic immunosuppressive therapy within the previous 5 years are not eligible - Patients considered by PIs/protocol team to have a complicated prior therapy or HCT regimen, or who have a low survival probability (e.g., refractory leukemia and/or undergoing 2nd HCT) - Poor risk disease/disease status including: chronic myeloid leukemia (CML) in blast crisis, acute myeloid leukemia (AML)/acute lymphoblastic leukemia (ALL) beyond 2nd remission, multiple myeloma, and aplastic anemia - Pregnant women and women who are lactating. Triplex risks to pregnant women are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the administered vaccine, also breastfeeding should be discontinued if the mother is enrolled on this study - Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., social/ psychological issues, etc. - Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics) |
Country | Name | City | State |
---|---|---|---|
United States | City of Hope Medical Center | Duarte | California |
Lead Sponsor | Collaborator |
---|---|
City of Hope Medical Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinically significant cytomegalovirus (CMV) reactivation prompting antiviral therapy or CMV disease | Will be defined by histology. Will compare vaccine and placebo regarding cumulative incidence of CMV events from first injection to day 180 post HCT using Gray's test. | From first injection to days 100 and 180 post-hematopoietic stem cell transplant (HCT) | |
Secondary | Non-relapse mortality | Cumulative incidence curves and Gray's test will be used. | At 365 days post-HCT | |
Secondary | Severe (grade 3-4) acute graft versus host disease (GVHD) | Up to day 365 post-HCT | ||
Secondary | Grade 3-4 adverse events | Adverse events probably or definitely related to the vaccination and modified vaccinia Ankara vector persistence will be evaluated. Final analysis of HCT-recipients safety will be based on comparison of vaccine and placebo regarding severe GVHD, immune reconstitution, and survival. Comparisons will be made using standard methods for right-censored data with interim analysis using standard group-sequential testing. Will plan a 2^0 analysis comparing event-free survival in both arms. | Up to 365 days post-HCT | |
Secondary | Duration of viremia | Repeated measures analyses will be used. | Up to day 200 post-HCT | |
Secondary | Duration of anti-CMV therapy | Repeated measures analyses will be used. | Up to day 200 post-HCT | |
Secondary | Peak CMV polymerase chain reaction value | Repeated measures analyses will be used. | Up to day 200 post-HCT | |
Secondary | Recurrence of CMV viremia | Repeated measures analyses will be used. | Up to day 200 post-HCT | |
Secondary | Incidence of late CMV reactivation or disease | Repeated measures analyses will be used. | At day 365 | |
Secondary | Time to engraftment | At day 365 | ||
Secondary | Incidence of acute GVHD | Cumulative incidence curves and Gray's test will be used. | At day 365 | |
Secondary | Incidence of chronic GVHD | Cumulative incidence curves and Gray's test will be used. | At day 365 | |
Secondary | Relapse | Cumulative incidence curves and Gray's test will be used. | At day 365 | |
Secondary | Non-relapse mortality | Cumulative incidence curves and Gray's test will be used. | At day 365 | |
Secondary | All-cause mortality | At day 365 | ||
Secondary | Infections | Cumulative incidence curves and Gray's test will be used. | At day 365 | |
Secondary | Overall survival | Will be compared using Kaplan-Meier curves and log-rank test. | At day 365 | |
Secondary | Levels and kinetics of CMV-specific T cell immunity | Levels and kinetics of CMV-specific T cell immunity combined with immunophenotyping and functional studies will be evaluated. | At day 365 | |
Secondary | Natural killer phenotype and function (cytotoxicity and cytokine production) | At day 365 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |